Cancer Biomarker Market
完整報告名稱與涵蓋範圍
Cancer Biomarker Market Size, Share & Trends Analysis Report, by Type of Biomarker (HER2, MET, EGFR, PD-L1, NTRK, ALK, Novel Biomarkers and Other Biomarkers), Type of Cancer (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia), By Region, Forecasts, 2025-2034
報告摘要
Valued at USD 28.5 Bn as of 2024, the global Cancer Biomarker Market is anticipated to climb to USD 44.5 Bn by 2034, reflecting a compound annual growth rate of 4.7% over the 2025–2034 period.
Cancer Biomarker encompasses The cancer biomarker market is witnessing rapid growth due to escalating cancer incidences and advancements in diagnostic technologies. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region anticipated to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Biomarkers Market Snapshot
Chapter 4. Global Cancer Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type of Biomarker Estimates & Trend Analysis
5.1. by Type of Biomarker & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Biomarker:
5.2.1. HER2
5.2.2. MET
5.2.3. EGFR
5.2.4. PD-L1
5.2.5. NTRK
5.2.6. ALK
5.2.7. Novel Biomarkers
5.2.8. Other Biomarkers
Chapter 6. Market Segmentation 2: by Type of Cancer Estimates & Trend Analysis
6.1. by Type of Cancer & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Cancer:
6.2.1. Breast Cancer
6.2.2. Prostate Cancer
6.2.3. Colorectum Cancer
6.2.4. Lung Cancer
6.2.5. Thyroid Cancer
6.2.6. Bladder Cancer
6.2.7. Melanoma
6.2.8. Non-Hodgkins Lymphoma
6.2.9. Endometrial Cancer
6.2.10. Kidney Cancer
6.2.11. Leukemia
Chapter 7. Cancer Biomarkers Market Segmentation 6: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.1.2. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.1.3. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.2.2. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.2.3. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.3.2. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.3.3. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.4.2. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.4.3. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.5.2. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.5.3. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Agilent
8.2.2. ARUP Laboratories
8.2.3. BioReference
8.2.4. Foundation Medicine
8.2.5. OncoDNA
8.2.6. Q² Solutions
8.2.7. Thermo Fisher Scientific
8.2.8. YuceBio
8.2.9. Asper Biogene
8.2.10. Caris Life Sciences
8.2.11. CeGaT
8.2.12. Genekor Medical
8.2.13. Guardant Health
8.2.14. Labcorp
8.2.15. MedGenome
8.2.16. NeoGenomics Laboratories
8.2.17. Nonacus
8.2.18. Oxford Gene Technology
8.2.19. Personal Genome Diagnostics
8.2.20. PhenoPath
8.2.21. Positive Biosciences
8.2.22. Quest Diagnostics
8.2.23. Tempus
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們